FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
Lawsuit Does Not Cite Overlap In Companies’ Portfolios
Executive Summary
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
You may also be interested in...
Stock Watch: Biopharma Caught In US Government Anti-Bundling Drive
Medicare price renegotiation and the FTC’s scrutiny of biopharma acquisitions have suppressed sector stock prices. But the sector may not be the actual target.
Amgen’s FTC Settlement To Allow $27.8bn Horizon Deal Closure Sets New M&A Precedent
Amgen agreed not to include Horizon’s Tepezza and Krystexxa in rebate bundling deals with payers, among other terms, so the FTC would clear the companies’ merger, giving pharma firms a new consideration in future dealmaking.
FTC Is Ready To Negotiate Over Amgen/Horizon Merger
Amgen asked the FTC to accept its pledge not to bundle Horizon’s Tepezza or Krystexxa, while an FTC administrative law judge urged a settlement between the agency and Amgen.